Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings
Authors: Warren, R. B., Gooderham, M., Lain, E., Bissonnette, R., Huang, Y. H., Ringuet, J., Hoffmann, M., Pinter, A., Merola, J. F., Rubens, J. H., Fan, D., Hsu, M. C., Li, S., Yang, Y. W., DeKlotz, C. M. C., & Song, E. J. Read more on pubmed
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD Study
Authors: Soung, J., Cui, Y., Bissonnette, R., Lebwohl, M. G., GonzĂĄlez-Cantero, Ă., Pinter, A., Rich, P., Prajapati, V. H., Miller-Kassamali, M., Cafone, J., Jiang, J., Li, S., Yang, Y. W., & Pink, A. E. Read more on pubmed
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis
Authors: David Strawn, James G Krueger, Robert Bissonnette, Kilian Eyerich, Laura K Ferris, Amy S Paller, Andreas Pinter, Dylan Richards, Elizabeth Y Chen, Kate Paget, Daniel Horowitz, Roohid Parast, Joshua J Rusbuldt, Jocelyn Sendecki, Sunita Bhagat, Lynn P Tomsho, Ching-Heng Chou, Marta E Polak, Brice E Keyes, Emily Bozenhardt, Yuan Xiong, Wangda Zhou, Cynthia DeKlotz, […]
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites
Authors: Gooderham M, Lain E, Bissonnette R, Huang YH, Lynde CW, Hoffmann M, Song EJ, Weirich O, Ceitlin RHG, Rubens JH, Delozier AM, Ota T, Hsu M-C, Li S, DeKlotz CMC, Nunes F, Warren RB Read more on pubmed
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
Authors: Bissonnette R, Soung J, Hebert AA, Pink AE, Pinter A, Moor AY, Shi Y, Wang W-H, Toth DP, Miller-Kassamali M, Cafone J, Jiang J, Li S, DeKlotz CMC, Nunes F, Lebwohl MG Read more on pubmed
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial.
Authors: Bissonnette R, Vender R, Pinter A, Stanley LM, Houts CR, Miller M, DeLozier AM, Li S, Iaconangelo C, Ferris LK. Read more on pubmed
Plaque Psoriasis Case Study
Click here for a PDF version of this case study Outcomes Indero successfully managed this plaque psoriasis study and this resulted in: Enrollment completion 5 months earlier than planned Study Characteristics Study Phase: II Patient Population: Plaque Psoriasis IP Route of Administration: Systemic Total Enrollment: 224 patients, 59 sites (North America & Europe)â […]
Late-Breaking Data on Icotrokinra Shows Promising Efficacy and Safety in Psoriasis
At the recent American Academy of Dermatology (AAD) Annual Meeting, Robert Bissonnette, MD, presented late-breaking data from the ICONIC-LEAD (NCT06095115) study evaluating icotrokinra, an oral IL-23 receptor antagonist, for patients with moderate-to-severe plaque psoriasis. The phase 3 study demonstrated significant efficacy at week 16, with further improvements observed through week 24. In an interview with […]
Nimbus Testimonial
Innovaderm is proud of its partnership with Nimbus Therapeutics for an investigational oral TYK2 inhibitor, in a Phase 2b trial for patients with moderate-to-severe psoriasis. Innovadermâs reputed teams once again proved their expertise throughout the whole project, from the study design all the way to the trial reports, under tight timelines. âThere are many CRO […]
Mission impossible? Caveats in interpreting and comparing long-term efficacy in biologic studies for moderate-to-severe plaque psoriasis
Authors: Langley RG, Egeberg A, Gooderham M, Bissonnette R, Ringuet J, Kalia S, Park-Wyllie L, Abbarin N, Tran D, Zara A, Yang YW, Strober B. Read more on pubmed
